Base de dados : MEDLINE
Pesquisa : D12.776.861.260 [Categoria DeCS]
Referências encontradas : 28 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 28 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25906123
[Au] Autor:Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
[Ad] Endereço:*El Camino Hospital Mountain, Department of Pathology, Mountain View, CA †Cell Marque, Rocklin, CA ‡Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA.
[Ti] Título:The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
[So] Source:Appl Immunohistochem Mol Morphol;24(4):229-37, 2016 Apr.
[Is] ISSN:1533-4058
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Traditional markers mammaglobin and GCDFP15 show good specificity but lack sensitivity and can be difficult to interpret in small tissue samples. We undertook a comparative study of the novel nuclear marker GATA3 (expression typically restricted to breast and urothelial carcinomas) and GCDFP15 and mammaglobin. We first compared quantitative mRNA expression levels of these 3 markers across a diverse set of over 6000 tumors and 500 normal samples from The Cancer Genome Atlas which showed dramatically higher GATA3 expression (>10-fold higher) in breast cancer as compared with GCDFP15 or mammaglobin (both P<2.2e-16), suggesting that GATA3 may represent a more sensitive marker of breast cancer than GCDFP15 or mammaglobin. We next examined protein expression by immunohistochemistry in 166 cases (including surgical and cytology specimens) of metastatic breast carcinoma and 54 cases with available matched primaries. One whole-slide section from each case was stained for monoclonal GATA3 (L50-823), monoclonal mammaglobin (31A5), and monoclonal GCDFP15 (EP1582Y). Staining intensity (0 to 3+) and extent (0% to 100%) were scored with an H-score calculated (range, 0 to 300). Sensitivities by varying H-score cutoffs for a positive result in metastatic breast carcinoma among GATA3/GCDFP15/mammaglobin, respectively, were as follows: any H-score=95%/65%/78%, H-score>50=93%/37%/47%, H-score>100=90%/25%/27%, H-score>150=86%/21%/19%, H-score>200=73%/18%/9%, H-score>250=66%/14%/6%. Significant staining differences by specimen type, tumor subtype/grade, or ER/PR/HER2 status were not identified. Significantly stronger correlation was observed between primary/metastatic GATA3 expression [Pearson's correlation=0.81 (0.68-0.89)] as compared with the primary/metastatic correlations of GCDFP15 [Pearson's correlation=0.57 (0.33-0.74)] and mammaglobin [Pearson's correlation=0.50 (0.24-0.70)] (both P<0.05). In conclusion, the novel marker GATA3 stains a significantly higher proportion of both primary and metastatic breast carcinomas than GCDFP15 or mammaglobin with stronger and more diffuse staining, helpful in cases with small tissue samples. The matched primary/metastatic expression of GATA3 is also more consistent. We propose that GATA3 be included among a panel of confirmatory markers for metastatic breast carcinoma.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/diagnóstico
Neoplasias da Mama/patologia
Proteínas de Transporte/metabolismo
Fator de Transcrição GATA3/metabolismo
Glicoproteínas/metabolismo
Mamoglobina A/metabolismo
Mamoglobina B/metabolismo
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama/metabolismo
Feminino
Seres Humanos
Meia-Idade
Metástase Neoplásica
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Carrier Proteins); 0 (GATA3 Transcription Factor); 0 (GATA3 protein, human); 0 (Glycoproteins); 0 (Mammaglobin A); 0 (Mammaglobin B); 0 (PIP protein, human)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150424
[St] Status:MEDLINE
[do] DOI:10.1097/PAI.0000000000000186


  2 / 28 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26679816
[Au] Autor:Pandey M; Kumar BV; Verma R
[Ad] Endereço:School of Animal Biotechnology, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab 141004, India.
[Ti] Título:Mammaglobin as a diagnostic serum marker of complex canine mammary carcinomas.
[So] Source:Res Vet Sci;103:187-92, 2015 Dec.
[Is] ISSN:1532-2661
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mammaglobin is a glycoprotein exhibiting homology to uteroglobin gene family. Although the biological function of the protein is not yet known it has been reported to act as marker for breast cancer in women. This study reports the expression of mammaglobin gene in canine mammary tumor condition. The gene was cloned, sequenced and heterologously expressed in Escherichia coli host system as 12 kDa (approx.) recombinant fusion protein. The expressed protein was further purified to homogeneity and confirmed by western blotting. Hyperimmune sera were raised against the expressed protein in rabbits and mice to standardize sandwich ELISA for relative quantification of circulating protein in the sera of dogs with mammary tumors. Based on receiver-operating characteristics analysis, the test was found to be 90% sensitive and 95% specific for a cut-off value of 0.177 with respect to histopathological staining in diagnosing canine mammary tumors and the protein level was not elevated in other diseased conditions. These findings indicate that it can act as a novel molecular marker for detecting mammary tumors in canines.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Carcinoma/veterinária
Mamoglobina B/sangue
Neoplasias Mamárias Animais/diagnóstico
Proteínas de Neoplasias/sangue
[Mh] Termos MeSH secundário: Animais
Carcinoma/diagnóstico
Carcinoma/genética
Cães
Ensaio de Imunoadsorção Enzimática/veterinária
Feminino
Neoplasias Mamárias Animais/genética
Curva ROC
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Mammaglobin B); 0 (Neoplasm Proteins)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151218
[Lr] Data última revisão:
151218
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151219
[St] Status:MEDLINE


  3 / 28 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25612011
[Au] Autor:Wong RL; Wang Q; Treviño LS; Bosland MC; Chen J; Medvedovic M; Prins GS; Kannan K; Ho SM; Walker CL
[Ad] Endereço:a Center for Translational Cancer Research; Institute of Biosciences and Technology ; The Texas A&M University System Health Science Center ; Houston , TX USA.
[Ti] Título:Identification of secretaglobin Scgb2a1 as a target for developmental reprogramming by BPA in the rat prostate.
[So] Source:Epigenetics;10(2):127-34, 2015.
[Is] ISSN:1559-2308
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Secretoglobins are a superfamily of secreted proteins thought to participate in inflammation, tissue repair, and tumorigenesis. Secretoglobin family 2A member 1 (Scgb2a1) is a component of prostatein, a major androgen-binding protein secreted by the rat prostate. Using a rat model for developmental reprogramming of susceptibility to prostate carcinogenesis, we identified, by RNA-seq, that Scgb2a1 is significantly upregulated (>100-fold) in the prostate of adult rats neonatally exposed to bisphenol A (BPA), with increased gene expression confirmed by quantitative RT-PCR and chromatin immunoprecipitation for histone H3 lysine 9 acetylation. Bisulfite analysis of both CpG islands located within 10 kb of the Scgb2a1 promoter identified significant hypomethylation of the CpG island upstream of the transcription start site of this gene in the reprogrammed prostate. These data suggest that expression of Scgb2a1 in the adult prostate could be epigenetically reprogrammed by BPA exposure during prostate development, with potential implications for cancer risk and response to chemotherapeutics associated with prostatein binding.
[Mh] Termos MeSH primário: Compostos Benzidrílicos/toxicidade
Reprogramação Celular/efeitos dos fármacos
Estrogênios não Esteroides/toxicidade
Mamoglobina B/metabolismo
Fenóis/toxicidade
Próstata/efeitos dos fármacos
Próstata/metabolismo
[Mh] Termos MeSH secundário: Acetilação
Animais
Animais Recém-Nascidos
Ilhas de CpG/efeitos dos fármacos
Metilação de DNA/efeitos dos fármacos
Histonas/metabolismo
Lisina/metabolismo
Masculino
Regiões Promotoras Genéticas/efeitos dos fármacos
Próstata/crescimento & desenvolvimento
Hiperplasia Prostática/induzido quimicamente
Ratos Sprague-Dawley
Regulação para Cima/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Benzhydryl Compounds); 0 (Estrogens, Non-Steroidal); 0 (Histones); 0 (Mammaglobin B); 0 (Phenols); 0 (Scgb2a1 protein, rat); K3Z4F929H6 (Lysine); MLT3645I99 (bisphenol A)
[Em] Mês de entrada:1510
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150123
[St] Status:MEDLINE
[do] DOI:10.1080/15592294.2015.1009768


  4 / 28 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24603286
[Au] Autor:Fischer K; von Brünneck AC; Hornung D; Denkert C; Ufer C; Schiebel H; Kuhn H; Borchert A
[Ad] Endereço:Institute of Biochemistry, University Medicine Berlin - Charité, CharitéCrossOver, Charitéplatz 1, Virchowweg 6, D-10117 Berlin, Germany.
[Ti] Título:Differential expression of secretoglobins in normal ovary and in ovarian carcinoma--overexpression of mammaglobin-1 is linked to tumor progression.
[So] Source:Arch Biochem Biophys;547:27-36, 2014 Apr 01.
[Is] ISSN:1096-0384
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Secretoglobins (SCGB), such as mammaglobin 1 (MGB1, SCGB2A2), mammaglobin 2 (MGB2, SCGB2A1) and lipophilin B (LIPB, SCGB1D2), have been related to carcinogenesis. We profiled expression of MGB1, MGB2 and LIPB in human tissues and ovarian carcinoma and explored the impact of SCGB overexpression on cell proliferation. MGB1, MGB2 and LIPB mRNA are expressed at variable levels in most human tissues and we observed significant bilateral correlations between the different secretoglobins. Concerted overexpression of MGB1 and LIPB resulted in significant increase in cell proliferation. In clinical specimens of ovarian carcinoma we measured elevated concentrations of secretoglobin mRNA and for MGB1 this up-regulation was confirmed on the protein level. Overexpression of MGB1 positively correlated with the FIGO stage, the tumor grade and the mitotic index suggesting a patho-physiological role of the protein. Our data indicate that MGB1, MGB2 and LIPB mRNAs are expressed at low levels in human tissues but basal expression is upregulated in ovarian cancer. The in vivo correlation between nuclear MGB1 localization and the mitotic rate in ovarian cancer as well as the increased cell proliferation induced by secretoglobin overexpression in ovarian cancer cell lines suggest a pathophysiological role of these proteins in ovarian cancer.
[Mh] Termos MeSH primário: Regulação Neoplásica da Expressão Gênica
Mamoglobina A/genética
Mamoglobina B/genética
Neoplasias Ovarianas/genética
Neoplasias Ovarianas/patologia
Ovário/patologia
Secretoglobinas/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Linhagem Celular Tumoral
Feminino
Seres Humanos
Mamoglobina A/análise
Mamoglobina B/análise
Meia-Idade
Ovário/metabolismo
Secretoglobinas/análise
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Mammaglobin A); 0 (Mammaglobin B); 0 (SCGB1D2 protein, human); 0 (SCGB2A1 protein, human); 0 (Secretoglobins)
[Em] Mês de entrada:1405
[Cu] Atualização por classe:140331
[Lr] Data última revisão:
140331
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140308
[St] Status:MEDLINE


  5 / 28 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24585249
[Au] Autor:Munakata K; Uemura M; Takemasa I; Ozaki M; Konno M; Nishimura J; Hata T; Mizushima T; Haraguchi N; Noura S; Ikenaga M; Okamura S; Fukunaga M; Murata K; Yamamoto H; Doki Y; Mori M
[Ad] Endereço:Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Japan.
[Ti] Título:SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance.
[So] Source:Int J Oncol;44(5):1521-8, 2014 May.
[Is] ISSN:1791-2423
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:We recently showed that liver metastatic tissue from patients with colorectal cancer (CRC) was a useful model for identifying novel, hypoxia-inducible genes and prognostic markers. We showed that the expression of secretoglobin, family 2A, member 1 (SCGB2A1) was a potential prognostic factor for CRC. Here, we further evaluated the prognostic impact and function of SCGB2A1 in 222 patients with CRC. The impact of SCGB2A1 expression on disease-free survival (DFS) and overall survival (OS) was assessed with mRNA expression profiling. The function of SCGB2A1 was analyzed by evaluating mRNA expression profiles in cells derived from patients with CRC and by testing the effects of transfecting SCGB2A1 into different CRC-derived cell lines. We evaluated the effects of SCGB2A1 on proliferation, chemosensitivity, radiation sensitivity and sphere formation. Univariate and multivariate analyses indicated that the expression of SCGB2A1 was an independent prognostic factor for CRC (p<0.05), together with lymph node metastasis (p<0.05). Enforced expression of SCGB2A1 in CRC-derived cell lines promoted proliferation (DLD1, SW480 and LoVo cells; p<0.05), decreased chemosensitivity to 5-fluorouracil and oxaliplatin (DLD1 and SW480 cell lines; p<0.05), and significantly increased the viability of irradiated cells (DLD1, SW480 and LoVo cell lines; p<0.05). SCGB2A1 expression was also correlated to cancer stemness-related genes (Wnt, Zeb1 and Twist). Consistent with this correlation, SCGB2A1 expressing cells (SW480) showed increased sphere formation (p<0.05). These results indicated that SCGB2A1 represented a novel, prognostic factor for CRC, and that expression of SCGB2A1 correlated with chemoresistance, radioresistance and cancer cell stemness.
[Mh] Termos MeSH primário: Neoplasias Colorretais/genética
Neoplasias Colorretais/patologia
Mamoglobina B/genética
Mamoglobina B/metabolismo
[Mh] Termos MeSH secundário: Idoso
Análise de Variância
Antineoplásicos/farmacologia
Linhagem Celular Tumoral
Neoplasias Colorretais/diagnóstico
Resistência a Medicamentos Antineoplásicos
Feminino
Fluoruracila/farmacologia
Regulação Neoplásica da Expressão Gênica
Proteínas de Homeodomínio/genética
Seres Humanos
Masculino
Meia-Idade
Compostos Organoplatínicos/farmacologia
Tolerância a Radiação
Fatores de Transcrição/genética
Proteína 1 Relacionada a Twist/genética
Proteínas Wnt/genética
Homeobox 1 de Ligação a E-box em Dedo de Zinco
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Homeodomain Proteins); 0 (Mammaglobin B); 0 (Organoplatinum Compounds); 0 (SCGB2A1 protein, human); 0 (Transcription Factors); 0 (Twist-Related Protein 1); 0 (Wnt Proteins); 0 (ZEB1 protein, human); 0 (Zinc Finger E-box-Binding Homeobox 1); 04ZR38536J (oxaliplatin); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1411
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140304
[St] Status:MEDLINE
[do] DOI:10.3892/ijo.2014.2316


  6 / 28 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23989997
[Au] Autor:Luyckx V; Durant JF; Camboni A; Gilliaux S; Amorim CA; Van Langendonckt A; Irenge LM; Gala JL; Donnez J; Dolmans MM
[Ad] Endereço:Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
[Ti] Título:Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study.
[So] Source:J Assist Reprod Genet;30(10):1289-99, 2013 Oct.
[Is] ISSN:1573-7330
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To assess the safety of reimplantation of cryopreserved ovarian tissue from advanced-stage breast cancer patients. METHODS: Cryopreserved ovarian cortical fragments were obtained from 13 advanced-stage breast cancer patients aged 17-35 years. After thawing, part of the ovarian cortical tissue was grafted to severe combined immunodeficient mice for 6 months. The presence of malignant mammary cells in ovarian tissue was evaluated after thawing as well as after grafting by 1) histology and immunohistochemistry (epithelial membrane antigen, Her2/neu and gross cystic disease fluid protein 15 identification), and 2) detection of the MGB2 gene by qPCR. RESULTS: No malignant cells were evidenced by histology and immunohistochemistry. None of the mice died during the 6-month grafting period, nor developed macroscopically visible masses. MGB2 gene expression was detected by qPCR and confirmed by sequencing in frozen-thawed ovarian tissue in 4 cases and in grafts in 1 case. CONCLUSIONS: This pilot study is the first to evaluate the risk of contamination of cryopreserved ovarian tissue from advanced-stage breast cancer patients by xenotransplantation for 6 months to immunodeficient mice, associated with more conventional screening methods. Our xenografting results are reassuring, but caution needs to be exercised, as MGB2 gene expression was detected in some cases. Larger numbers of ovarian tissue samples from patients with advanced-stage breast cancer are required to confirm our findings before ovarian tissue transplantation can be contemplated in these patients.
[Mh] Termos MeSH primário: Neoplasias da Mama/patologia
Preservação da Fertilidade/métodos
Folículo Ovariano/transplante
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso de 80 Anos ou mais
Animais
Proteínas de Transporte/metabolismo
Criopreservação
Feminino
Glicoproteínas/metabolismo
Seres Humanos
Mamoglobina B/biossíntese
Mamoglobina B/genética
Camundongos
Camundongos SCID
Projetos Piloto
Receptor ErbB-2/metabolismo
Transplante Heterólogo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Carrier Proteins); 0 (Glycoproteins); 0 (Mammaglobin B); 0 (PIP protein, human); 0 (SCGB2A1 protein, human); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2)
[Em] Mês de entrada:1407
[Cu] Atualização por classe:150423
[Lr] Data última revisão:
150423
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130831
[St] Status:MEDLINE
[do] DOI:10.1007/s10815-013-0065-3


  7 / 28 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23807163
[Au] Autor:Bellone S; Tassi R; Betti M; English D; Cocco E; Gasparrini S; Bortolomai I; Black JD; Todeschini P; Romani C; Ravaggi A; Bignotti E; Bandiera E; Zanotti L; Pecorelli S; Ardighieri L; Falchetti M; Donzelli C; Siegel ER; Azodi M; Silasi DA; Ratner E; Schwartz PE; Rutherford TJ; Santin AD
[Ad] Endereço:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8063, USA.
[Ti] Título:Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy.
[So] Source:Br J Cancer;109(2):462-71, 2013 Jul 23.
[Is] ISSN:1532-1827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We studied the genetic fingerprints of ovarian cancer and validated the potential of Mammaglobin b (SCGB2A1), one of the top differentially expressed genes found in our analysis, as a novel ovarian tumour rejection antigen. METHODS: We profiled 70 ovarian carcinomas including 24 serous (OSPC), 15 clear-cell (CC), 24 endometrioid (EAC) and 7 poorly differentiated tumours, and 14 normal human ovarian surface epithelial (HOSE) control cell lines using the Human HG-U133 Plus 2.0 chip (Affymetrix). Quantitative real-time PCR and immunohistochemistry staining techniques were used to validate microarray data at RNA and protein levels for SCGB2A1. Full-length human-recombinant SCGB2A1 was used to pulse monocyte-derived dendritic cells (DCs) to stimulate autologous SCGB2A1-specific cytotoxic T-lymphocyte (CTL) responses against chemo-naive and chemo-resistant autologous ovarian tumours. RESULTS: Gene expression profiling identified SCGB2A1 as a top differentially expressed gene in all histological ovarian cancer types tested. The CD8+ CTL populations generated against SCGB2A1 were able to consistently induce lysis of autologous primary (chemo-naive) and metastatic/recurrent (chemo-resistant) target tumour cells expressing SCGB2A1, whereas autologous HLA-identical noncancerous cells were not lysed. Cytotoxicity against autologous tumour cells was significantly inhibited by anti-HLA-class I (W6/32) monoclonal antibody. Intracellular cytokine expression measured by flow cytometry showed a striking type 1 cytokine profile (i.e., high IFN-γ secretion) in SCGB2A1-specific CTLs. CONCLUSION: SCGB2A1 is a top differentially expressed gene in all major histological types of ovarian cancers and may represent a novel and attractive target for the immunotherapy of patients harbouring recurrent disease resistant to chemotherapy.
[Mh] Termos MeSH primário: Antígenos de Neoplasias/metabolismo
Biomarcadores Tumorais/metabolismo
Mamoglobina B/metabolismo
Neoplasias Ovarianas/metabolismo
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antígenos de Neoplasias/genética
Biomarcadores Tumorais/genética
Feminino
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Imunoterapia
Mamoglobina B/genética
Análise em Microsséries
Meia-Idade
Neoplasias Ovarianas/patologia
Neoplasias Ovarianas/terapia
Transcriptoma
Estudos de Validação como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Biomarkers, Tumor); 0 (Mammaglobin B); 0 (SCGB2A1 protein, human)
[Em] Mês de entrada:1310
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130629
[St] Status:MEDLINE
[do] DOI:10.1038/bjc.2013.315


  8 / 28 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23332923
[Au] Autor:Luo MH; Huang YH; Ni YB; Tsang JY; Chan SK; Shao MM; Tse GM
[Ad] Endereço:Department of Pathology, Peking University Shenzhen Hospital, Shenzhen, China 518036.
[Ti] Título:Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas.
[So] Source:Hum Pathol;44(7):1241-50, 2013 Jul.
[Is] ISSN:1532-8392
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Immunohistochemical analysis of gross cystic disease fluid protein-15 (GCDFP-15) and mammaglobin (MGB) is frequently used in routine practice for assessment of metastases or regional recurrences of breast origin. Breast cancer is highly heterogeneous. Expression of these 2 markers in various breast cancer subtypes has not been well studied. In addition, the usefulness of these two markers in combination in detecting breast origin has not been explored. In this study, a large cohort of breast cancers was evaluated for GCDFP-15 and MGB expression, both individually and combined. Their expression was correlated with cancer subtypes, other biomarkers and clinicopathologic parameters. A higher sensitivity for MGB (42.3%) than GCDFP-15 (31.6%) in detecting cancers of breast origin was observed. Combining both increased the sensitivity further, both for primary tumor (53.0%) and for nodal metastases (69.0%). GCDFP-15 was associated significantly with a breast cancer profile of good prognosis tumors, including lower grade (P < .001), pN (P = .029) and Ki-67 (P < .001) as well as negative basal markers expression (P = .043, .009, and .049 for c-Kit, CK5/6 and epidermal growth factor receptor, respectively) and, thus, may not be sensitive for detection of poor prognosis tumors. MGB has the highest expression in HER2-overexpressing cancers (56.6%), and may be a potentially useful marker for this subtype. Nonetheless, both markers showed low expression in the basal like (BLBC) subtype (11.9% and 21.4% for GCDFP-15 and MGB respectively), therefore, the detection of BLBC remains problematic. Negative results need to be interpreted with caution, and correlation with other clinical findings may be required to exclude the possibility of metastatic BLBC.
[Mh] Termos MeSH primário: Neoplasias da Mama/metabolismo
Carcinoma Ductal de Mama/metabolismo
Carcinoma Intraductal não Infiltrante/metabolismo
Proteínas de Transporte/metabolismo
Glicoproteínas/metabolismo
Mamoglobina B/metabolismo
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/patologia
Carcinoma Ductal de Mama/secundário
Carcinoma Intraductal não Infiltrante/secundário
Feminino
Seres Humanos
Linfonodos/metabolismo
Metástase Linfática
Meia-Idade
Prognóstico
Análise Serial de Tecidos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Carrier Proteins); 0 (Glycoproteins); 0 (Mammaglobin B); 0 (PIP protein, human)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130122
[St] Status:MEDLINE


  9 / 28 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22716011
[Au] Autor:Wallenfels I; Chlumská A
[Ad] Endereço:Medicyt Laboratory Trencin, Slovak Republic. zamecnikm@seznam.cz
[Ti] Título:Vaginal myofibroblastoma with glands expressing mammary and prostatic antigens.
[So] Source:Cesk Patol;48(1):40-3, 2012 Jan.
[Is] ISSN:1210-7875
[Cp] País de publicação:Czech Republic
[La] Idioma:eng
[Ab] Resumo:A case of unusual vaginal myofibroblastoma containing glands which expressed mammary and prostatic markers is described. The tumor occurred in 70-year-old woman in the proximal third of the vagina. It showed morphology and immunophenotype typical of so-called cervicovaginal myofibroblastoma. The peripheral zone of the lesion contained a few groups of glands suggesting vaginal adenosis or prostatic-type glands on initial examination. The glands showed a surprising simultaneous expression of mammary markers mammaglobin and GCDFP-15 and prostatic markers prostate-specific antigen (PSA) and prostate-specific acid phosphatase (PSAP). Immunostains for alpha-smooth muscle actin, p63 and CD10 highlighted the myoepithelial cell layer of the glands. The finding indicates that simultaneous use of both mammary and prostatic markers for examination of unusual glandular lesions in the vulvovaginal location can be helpful for an exact diagnosis, and can contribute to better understanding of prostatic and mammary differentiations in the female lower genital tract.
[Mh] Termos MeSH primário: Proteínas de Transporte/secreção
Glicoproteínas/secreção
Mamoglobina A/secreção
Mamoglobina B/secreção
Neoplasias de Tecido Muscular/patologia
Neoplasias Vaginais/patologia
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Imuno-Histoquímica
Neoplasias de Tecido Muscular/secreção
Neoplasias Vaginais/secreção
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Carrier Proteins); 0 (Glycoproteins); 0 (Mammaglobin A); 0 (Mammaglobin B); 0 (PIP protein, human)
[Em] Mês de entrada:1211
[Cu] Atualização por classe:160510
[Lr] Data última revisão:
160510
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120622
[St] Status:MEDLINE


  10 / 28 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:19635143
[Au] Autor:Tassi RA; Calza S; Ravaggi A; Bignotti E; Odicino FE; Tognon G; Donzelli C; Falchetti M; Rossi E; Todeschini P; Romani C; Bandiera E; Zanotti L; Pecorelli S; Santin AD
[Ad] Endereço:Division of Gynecologic Oncology, Department Materno Infantile e Tecnologie Biomediche, University of Brescia, Brescia, Italy. renata.tassi03@gmail.com
[Ti] Título:Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence.
[So] Source:BMC Cancer;9:253, 2009 Jul 27.
[Is] ISSN:1471-2407
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Traditional prognostic factors in epithelial ovarian cancer (EOC) are inadequate in predicting recurrence and long-term prognosis, but genome-wide cancer research has recently provided multiple potentially useful biomarkers. The gene codifying for Mammaglobin B (MGB-2) has been selected from our previous microarray analysis performed on 19 serous papillary epithelial ovarian cancers and its expression has been further investigated on multiple histological subtypes, both at mRNA and protein level. Since, to date, there is no information available on the prognostic significance of MGB-2 expression in cancer, the aim of this study was to determine its prognostic potential on survival in a large cohort of well-characterized EOC patients. METHODS: MGB-2 expression was evaluated by quantitative real time-PCR in fresh-frozen tissue biopsies and was validated by immunohistochemistry in matched formalin fixed-paraffin embedded tissue samples derived from a total of 106 EOC patients and 27 controls. MGB-2 expression was then associated with the clinicopathologic features of the tumors and was correlated with clinical outcome. RESULTS: MGB-2 expression was found significantly elevated in EOC compared to normal ovarian controls, both at mRNA and protein level. A good correlation was detected between MGB-2 expression data obtained by the two different techniques. MGB-2 expressing tumors were significantly associated with several clinicopathologic characteristics defining a less aggressive tumor behavior. Univariate survival analysis revealed a decreased risk for cancer-related death, recurrence and disease progression in MGB-2-expressing patients (p < 0.05). Moreover, multivariate analysis indicated that high expression levels of MGB-2 transcript (HR = 0.25, 95%, 0.08-0.75, p = 0.014) as well as positive immunostaining for the protein (HR = 0.41, 95%CI, 0.17-0.99, p = 0.048) had an independent prognostic value for disease-free survival. CONCLUSION: This is the first report documenting that MGB-2 expression characterizes less aggressive forms of EOC and is correlated with a favorable outcome. These findings suggest that the determination of MGB-2, especially at molecular level, in EOC tissue obtained after primary surgery can provide additional prognostic information about the risk of recurrence.
[Mh] Termos MeSH primário: Epitélio/metabolismo
Regulação Neoplásica da Expressão Gênica
Proteínas da Mielina/biossíntese
Proteínas da Mielina/fisiologia
Neoplasias Ovarianas/metabolismo
Proteolipídeos/biossíntese
Proteolipídeos/fisiologia
Uteroglobina/biossíntese
Uteroglobina/fisiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais
Estudos de Coortes
Feminino
Seres Humanos
Imuno-Histoquímica/métodos
Mamoglobina B
Meia-Idade
Neoplasias Ovarianas/diagnóstico
Prognóstico
Recidiva
Risco
Secretoglobinas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Mammaglobin B); 0 (Myelin Proteins); 0 (Proteolipids); 0 (SCGB2A1 protein, human); 0 (Secretoglobins); 9060-09-7 (Uteroglobin)
[Em] Mês de entrada:0912
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090729
[St] Status:MEDLINE
[do] DOI:10.1186/1471-2407-9-253



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde